Please click on a link below to learn more about the research being done or to find contact information.
Study Title: CHAMPION PHOENIX
A clinical trial comparing cangrelor to clopidogrel (Plavix®) standard of care therapy in subjects who require percutaneous coronary intervention.
Robert Iwaoka, MD (Novant Health Heart and Vascular Institute), Dustin Letts, MD (Novant Health Heart and Vascular Institute)
What is the purpose of the study?
The primary objective of this study is to demonstrate that in patients requiring percutaneous coronary intervention (PCI), cangrelor provides superior efficacy to clopidogrel (Plavix®) standard of care. Study also wants to demonstrate that cangrelor has an acceptable safety profile without excessive periprocedural bleeding. Cangelor is an intravenous medication that provides almost immediate platelet inhibition to protect against clots in heart arteries, which could lead to heart attack. Once medication is stopped, full recovery of platelet function within 60 minutes. Oral medications take longer to start working and to leave patients' systems.
Who is eligible?
Patients at least 18 years of age with stable angina (SA), non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and ST-segment elevation myocardial infarction (STEMI) who require PCI ( percutaneous coronary intervention ) and have not previously received a P2Y12 inhibitor ( drugs like Plavix® or Effient®).